Hospital
Charles a Cannon JR Memorial Hospital INC.
Charles a Cannon JR Memorial Hospital INC. was paid $752K by Medicaid between Jan 2018 and Nov 2024, across 36 billing codes. Its largest line is 99283, emergency room visit (moderate) — 55% of everything it billed.
33Billing provider infoCHARLES A CANNON JR MEMORIAL HOSPITAL INC.
LINVILLE, NC 28646
LINVILLE, NC 28646
33aNPI1225088255assigned 05/11/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$752K
24GClaims8,471
24DCodes billed36
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#76 of 92
Median peer was paid$11.47M
This provider vs. median0.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LONG, MARY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,895 | $128K | |
| 2019 | 958 | $105K | |
| 2020 | 855 | $131K | |
| 2021 | 887 | $82K | |
| 2022 | 1,187 | $95K | |
| 2023 | 1,108 | $115K | |
| 2024incomplete | 1,581 | $97K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 55% | 2,825 | 2,577 | $413K |
| 41899 | Unlisted procedure, dentoalveolar structures | 22% | 111 | 108 | $164K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 12% | 921 | 873 | $93K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.4% | 153 | 132 | $33K |
| J3490 | Unclassified drugs | 1.8% | 586 | 196 | $13K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.2% | 63 | 53 | $9K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 1,324 | 1,213 | $8K |
| 80053 | Comprehensive metabolic panel | <1% | 482 | 433 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,093 | 979 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 87 | 71 | $2K |
| 87634 | <1% | 12 | 12 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 12 | 12 | $1K |
24 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13 | $965.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 29 | $784.20 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 12 | $783.11 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14 | $732.85 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 51 | $544.18 |
| J2704 | Injection, propofol, 10 mg | <1% | 18 | $529.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 86 | $526.05 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 15 | $516.46 |
| 71045 | Radiologic examination, chest; single view | <1% | 13 | $495.95 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14 | $397.28 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14 | $397.28 |
| 81001 | <1% | 164 | $341.61 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 58 | $325.19 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15 | $284.34 |
| 86803 | <1% | 15 | $249.06 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 78 | $244.14 |
| 80306 | <1% | 14 | $240.63 | |
| 80061 | Lipid panel | <1% | 15 | $233.80 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 96 | $189.62 |
| 84439 | <1% | 15 | $157.36 | |
| 83605 | <1% | 13 | $144.07 | |
| 86701 | <1% | 14 | $143.78 | |
| 86592 | <1% | 14 | $74.34 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12 | $59.94 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLONG, MARY (SR VP MEDICAL STAFF RELATIONS)
Parent organizationAPPALACHIAN REGIONAL HEALTHCARE SYSTEM
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.